Trial Profile
A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthritis receiving non-biologic background disease-modifying antirheumatic drugs.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2014
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Genmab
- 28 Jun 2011 New trial record